Novel zein-PGA encapsulation technology for beverage ingredients
A self-assembly encapsulation technology using zein protein and propylene glycol alginate (PGA) to protect and deliver bioactive compounds in beverage systems. The platform enables tunable encapsulation of both fat-soluble and water-soluble ingredients with high loading capacity and long-term stability.
Overview
This encapsulation technology leverages the natural self-assembly of zein, a hydrophobic corn protein, with propylene glycol alginate (PGA) to form stable solid particles around bioactive ingredients. The resulting composite particles protect sensitive compounds such as phenolics and fat-soluble bioactives, enabling their incorporation into beverage formulations without degradation. By adjusting the assembly method, the technology can accommodate ingredients with different solubility profiles, making it versatile for a wide range of beverage applications.
Technical specifications
Core technology:
- Zein-PGA composite particles formed through anti-solvent or pH-driven self-assembly
- Particle sizes of approximately 1.0 µm via anti-solvent method and 0.7 µm via pH-driven method
- High-pressure microfluidization reduces particle size to approximately 0.3 µm for enhanced encapsulation and stability
- Verified loading capacity of 10-20% for phenolic compounds
- Demonstrated colloidal and thermal stability for more than 30 days
Key features:
- Tunable encapsulation approach adaptable to both fat-soluble and water-soluble bioactive ingredients
- PGA serves as a surface-active stabilizer, providing emulsification and colloidal stability in acidic beverage systems
- Solvent-free or low-solvent preparation options depending on ingredient characteristics
- Scalable process suitable for industrial beverage production
Technology readiness level
The technology has been validated at the laboratory scale, with confirmed particle formation, encapsulation efficiency, and short-term stability. A one-year proof-of-concept study is planned to optimize formulation for acidic pH conditions and heating treatments, fine-tune encapsulation efficiency for target ingredients, evaluate scale-up production and cost-effectiveness, and verify performance in real beverage systems. The technology is currently at an early-to-mid development stage, moving toward pilot-scale validation and commercial readiness.
About University of Connecticut
UConn is a comprehensive public research university and the state’s flagship, with its main campus in Storrs and an academic medical center in Farmington. Industry engages through UConn Tech Park—anchored by the Innovation Partnership Building—with shared labs, pilot‑scale testbeds, and advanced prototyping for collaborators. Integration with UConn Health enables clinical collaborations and translation, while Hartford and Stamford campuses connect companies to talent along the New York–Boston corridor; a statewide extension network supports technology adoption. Research is supported by competitive federal funding from agencies such as NIH, NSF, DOE, USDA, and DOD. A dedicated technology commercialization office and the Technology Incubation Program support IP, licensing, and startup incubation across multiple sites.
delivered to your inbox.